To hear about similar clinical trials, please enter your email below
Trial Title:
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
NCT ID:
NCT06132191
Conditions: Official terms:
Cemiplimab
Study type:
Expanded Access
Overall status:
Available
Intervention:
Intervention type:
Drug
Intervention name:
Cemiplimab
Other name:
REGN2810
Summary:
Provide expanded access of cemiplimab in patients with solid tumors
Detailed description:
Compassionate Use requests are only being considered in response to Individual Patient
Investigational New Drug (IND) applications. Availability will depend on location.
Criteria for eligibility:
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Lead sponsor:
Agency:
Regeneron Pharmaceuticals
Agency class:
Industry
Source:
Regeneron Pharmaceuticals
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06132191
